Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + osimertinib versus osimertinib as first-line treatment for EGFR-mutated advanced or metastatic non-squamous NSCLC
CTR20243986Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Nov 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Nov 2024; status: active.
02
Drugs
sacituzumab tirumotecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243986.